Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TropicALL thromboprophylaxis study in pediatric acute lymphoblastic leukemia
NL-OMON44520Phase 3Withdrawn
- Sponsor
- SKion
- Start
- Nov 2014
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nadroparin in venous thromboembolism (VTE) (2 arms), sponsored by SKion. Primary endpoint: Incidence of symptomatic objectified venous thromboembolism. Planned start Nov 2014; status: withdrawn.
02
Drugs
nadroparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NL-OMON44520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44520.